6% SUBORDINATED CONVERTIBLE DEBENTURE DUE 2018Boston Therapeutics, Inc. • May 2nd, 2017 • Pharmaceutical preparations • New York
THIS 6% SUBORDINATED CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued 6% Subordinated Convertible Debentures of Boston Therapeutics, Inc., a Delaware corporation, (the “Company”), having its principal place of business at 354 Merrimack Street, #4, Lawrence, MA 01843, designated as its 6% Subordinated Convertible Debenture due 2019 (this debenture, the “Debenture” and, collectively with the other debentures of such series, the “Debentures”). The terms not defined herein shall have the meaning as set forth in the Purchase Agreement.
BOSTON THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 2nd, 2017 • Boston Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (the “Agreement”) is entered into by and between Boston Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned purchaser (the “Purchaser”) as of the latest date set forth on the signature page hereto.
ContractStock Purchase Warrant • May 2nd, 2017 • Boston Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT AND/OR APPLICABLE STATE SECURITIES LAWS, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED OR UNLESS SOLD PURSUANT TO RULE 144 OF SUCH ACT.
